NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
Merry Christmas and Happy New Year!
NovaMedica registers two own-development CNS products, one without equivalents in Russia and the other – in the world
4 Key Priorities for the European Medicines Agency in 2023
CRISPR-based microbial gene therapy delivers promise
FDA Releases Final Guidance on Adjusting for Covariates in Randomized Clinical Trials